Nurix Therapeutics Announces Upcoming Presentation of NX-5948 Preclinical Data at the EULAR 2021 Virtual Congress
21 mai 2021 07h00 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, May 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that preclinical...
New ACR White Paper Highlights Health Care Challenges Affecting the Rheumatic Disease Community
12 mai 2021 12h28 HE
|
American College of Rheumatology
Atlanta, May 12, 2021 (GLOBE NEWSWIRE) -- The American College of Rheumatology (ACR) today announced the launch of a new white paper, “Rheumatic Diseases in America: Confronting the Challenge,”...
Exagen Inc. Reports First Quarter 2021 Results
11 mai 2021 16h05 HE
|
Exagen Inc.
Quarterly Records: AVISE® CTD Volumes, Ordering Healthcare Providers and Adopters SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing...
Exagen Inc., Allegheny Health Network Research Institute and AHN Autoimmunity Institute Announce Collaboration to Develop Novel Patented Biomarkers into Clinical Diagnostic Tests
04 mai 2021 16h05 HE
|
Exagen Inc.
SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, Allegheny Health Network (AHN) Research Institute and the AHN Autoimmunity...
Exagen Announces New Campaign and Initiatives for Lupus Awareness Month
03 mai 2021 08h25 HE
|
Exagen Inc.
SAN DIEGO, May 03, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of...
Exagen to Announce First Quarter 2021 Financial Results on May 11, 2021
27 avr. 2021 16h05 HE
|
Exagen Inc.
SAN DIEGO, April 27, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2021 after...
Exagen Inc. Announces Study on the Long-Term Effects of COVID-19 Infection in the Development of Autoimmune Diseases
29 mars 2021 08h25 HE
|
Exagen Inc.
SAN DIEGO, March 29, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today...
Exagen Inc. Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
25 mars 2021 16h15 HE
|
Exagen Inc.
SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has closed its previously announced underwritten...
Exagen Inc. Reports Fourth Quarter and Full Year 2020 Results
16 mars 2021 16h05 HE
|
Exagen Inc.
SAN DIEGO, March 16, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year...
Exagen to Announce Fourth Quarter and Full Year Financial Results on March 16, 2021
02 mars 2021 08h00 HE
|
Exagen Inc.
SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, will release financial results for the quarter and year ended December 31, 2020 after the...